基线IPSS-M与移植前风险降级在MDS异基因移植中的预后价值
该回顾性研究纳入176例接受去甲基化药物(HMA)治疗后行异基因造血干细胞移植(alloHSCT)的骨髓增生异常综合征(MDS)患者,在诊断时和移植前分别应用分子国际预后评分系统(IPSS-M)。风险改善者生存未优于风险不变者,而风险恶化者预后更差。
要点
- 风险改善者4年PFS与风险不变者均为50%,风险恶化者为31%。
- TP53突变清除未转化为移植后结局改善。
核心结论
- 在HMA治疗的MDS患者中,alloHSCT前IPSS-M动态再评估较诊断时基线评估无预后优势。
- 风险降级不应视为治疗目标或试验终点,而风险进展为不良标志。
研究设计与样本
- 回顾性研究纳入176例HMA治疗后接受alloHSCT的MDS患者。
- 在诊断时和移植前分别应用IPSS-M评分,主要终点为4年PFS。
主要发现
- 风险改善、不变、恶化三组4年PFS分别为50%、50%、31%。
- TP53野生型患者中风险改善未带来生存获益,TP53突变清除未改善移植后结局。
关键数值与推荐
- 风险改善者4年PFS 50%,风险不变者50%,风险恶化者31%。
临床怎么用
- 风险进展者可考虑移植后维持策略或强化预处理以改善生存。
- 不应将IPSS-M风险降级作为治疗目标或试验终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Risk stratification in myelodysplastic syndromes (MDS) is essential for clinical decision-making, yet the optimal approach to estimate risk for patients undergoing allogeneic stem cell transplantation (alloHSCT) remains uncertain. Whether dynamic changes in risk between diagnosis and post-hypomethylating agent (HMA) therapy improve prognostic accuracy beyond baseline evaluation has not been established. We retrospectively studied 176 HMA-treated patients who underwent alloHSCT, applying the Molecular International Prognostic Scoring System (IPSS-M) at both diagnosis and before transplant. The primary end point was 4-year progression-free survival (PFS). Overall, dynamic assessment did not improve prognostic performance compared with baseline evaluation. For 4-year PFS, C-indices at diagnosis vs at alloHSCT were 0.6406 vs 0.6377 (P = .82). Patients with worsening risk after HMA experienced notably inferior outcomes, whereas those with apparent improvement fared no better than patients with unchanged risk (4-year PFS: 50%, 50%, and 31% for improved, unchanged, and worsening risk, respectively). Apparent IPSS-M improvement before alloHSCT yielded no gains in survival and no reduction in relapse relative to unchanged risk, a pattern consistent among TP53 wild-type patients. Moreover, clearance of TP53 mutations after HMA therapy did not translate into improved posttransplant outcomes. In summary, dynamic reassessment with IPSS-M before alloHSCT offers no prognostic advantage over baseline evaluation at diagnosis in HMA-treated patients with MDS. Accordingly, risk reduction should not be regarded as a therapeutic goal or trial end point, whereas risk progression constitutes an adverse marker that may inform incorporation of posttransplant maintenance strategies or intensified conditioning regimens to improve survival.
引用
- Aguirre LE, Kim HT, Elmariah H, et al. Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation. Blood Adv. 2026. PMID: 41587470. doi:10.1182/bloodadvances.2025018431
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。